New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
16:01 EDTLJPCLa Jolla announces completion of enrollment of Phase 2 study of GCS-100
La Jolla Pharmaceutical announced that it has completed enrollment of GCS-100-CS-4003, its Phase 2 Extension study of GCS-100 in chronic kidney disease. The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study. A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
08:01 EDTLJPCLa Jolla reports first patient enrolled in LJPC-501 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use